VitalTrace has had the pleasure of participating in iPREP WA's Industry and PhD Research and Engagement Program. We were fortunate to work with our very own “Dream Team”; Alvin Lee, Saman Akbar Zadeh and Georgios Mavropalias, bringing their expertise in signal processing, data science and biomedical science respectively.
No items found.
No items found.
Another win for VitalTrace through BioMedTech Horizons
VitalTrace and our associated partners are honoured to announce that our BioMedTech Horizons bid has been successfully awarded a $797,276 grant from the MTPConnect and Dr Daniel Grant.
September 23, 2021
•
3 min read
VitalTrace and our associated partners are honoured to announce that our BioMedTech Horizons bid has been successfully awarded a $797,276 grant from the MTPConnect and Dr Daniel Grant. This funding will accelerate VitalTrace's capacity to create prototype devices, fast-tracking our steps to commercialisation ready for advanced manufacturing and clinical trials activity.
MTPConnect Managing Director and CEO, Dr Daniel Grant, says this round focused predominantly on the development of pre-commercial prototypes that are entering human clinical trials.
“From the five selected projects, patients of the future are set to benefit from new medical devices for blindness and vision impairment, improved neonatal resuscitation, precision monitoring of fetal complications during birth, real-time atrial fibrillation/cardiac monitoring for patients at home and patient matched spinal implants,” Dr Grant said.
Read the announcement here.
We are excited by the opportunity this funding presents to improve the future of childbirth monitoring!
No items found.
VitalTrace's DelivAssure featured on national news as a potential breakthrough
Our continuous lactate monitor for childbirth, DelivAssure, has been featured on a number of media platforms, including the ABC, as a potential breakthrough.
July 25, 2025
•
3 min read
A breakthrough in childbirth care and a proud moment for the VitalTrace team. Our continuous lactate monitor for childbirth, DelivAssure, has been featured on a number of media platforms, including the ABC, as a potential breakthrough.
A moment of thanks on the achievement of the recent clinical trials:
We want to especially thank our Chief Medical Officer Jonathan Morris, the tireless Sharon McCracken, and our long-time collaborator Jane Pillow, who have been integral to our progress.
Thank you to our Principal Investigators across our clinical trials: A/Professor Sean Seeho, Penny Sheehan, Daniel Rolnik and Scott White. We’re incredibly grateful to the clinical teams and hospitals who made these trials possible across Royal North Shore Hospital, Monash Health, King Edward Memorial Hospital and Box Hill Hospital - Eastern Health.
The mothers and babies who took part in our trials are also at the heart of our work. We are endlessly appreciative for their participation.
Also with thanks to our partners and supporters: The University of Western Australia, University of Sydney, University of Technology Sydney, Australian Government and Government of Western Australia's Future Health Research and Innovation (FHRI) and Department of Jobs, Tourism, Science and Innovation (JTSI), Fund WA and Artesian (Alternative Investments).
Most of all, a huge thank you to our entire VitalTrace team whose hard work and dedication everyday have lead to this outcome.
No items found.
Using technology for better obstetric decision making
A wonderful feature from one of VitalTrace's clinical and commercial advisors, Vinayak Smith, on the role of innovative technologies to reduce the risk of litigation in obstetrics!
September 24, 2020
•
3 min read
A wonderful feature from one of VitalTrace's clinical and commercial advisors, Vinayak Smith, on the role of innovative technologies to reduce the risk of litigation in obstetrics!
“Cardiotocography (CTG) has been used for foetal heartrate (FHR) surveillance since the 1970s, as a means of detecting foetal hypoxia and guiding clinical decisions around delivery timing.
Despite the length of its usage, there is yet to be convincing evidence that CTG reduces birth asphyxia, stillbirths, caesareans or instrumental deliveries.
Although the technology is good at providing reassurance when foetal heartrates are ‘normal’, it is less useful at working out the prognosis of ‘abnormal’ heartrates, explains Dr. Vinayak Smith, of Monash University and the Royal Australian and New Zealand College of Obstetricians and Gynaecologists.
“It is not easy for two clinicians to agree or interpret the same CTG output the same way,” said Dr. Smith ahead of the Obstetric Malpractice Conference.
“Heartrates which look normal are easy to trust, whereas abnormal ones could mean anything. The CTG doesn’t tell us how worried we should be when a heartrate doesn’t look quite right.
“As a result, FHR red flags can be wrongfully dismissed by the clinician, leading to ‘preventable’ delivery complications or, in extreme cases, foetal deaths.
“Conversely, false alarms can lead to unnecessary clinical intervention and greater numbers of (precautionary) C-sections – a procedure which is risky for both mother and baby.”
Aside from the risk of healthcare complications, CTG reliability issues expose clinicians to legal culpability.
With 20 percent of obstetrics claims involving CTG – and obstetrics accounting for a significant proportion of medico legal disputes – it is widely agreed that better foetal monitoring solutions are needed.”